Teva

News

Illustration of a nerve cell on a colored background with light effects

EU panel rejects Pfizer's tanezumab for osteoarthritis pain

Any lingering hope that Pfizer may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor tanezumab looks to have been dashed after the EMA's human medicines committe

News

Teva faces EU antitrust probe over MS drug Copaxone

The European Commission has formally opened an antitrust investigation into Teva, which will assess whether the pharma company illegally delayed launches and use of generic versions of its

News

EU fines Teva and Cephalon €60.5m for 'pay for delay' scheme

The European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for delay” scheme that prevented cheaper generic competition for its sleep disorder dru

News

NICE backs Lilly’s Emgality for migraine, adding pressure on...

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve th

News

Gilead pays $97m to resolve US illegal kickback claims

Gilead has paid $97 million to resolve claims by US authorities that it acted illegally by using a charitable foundation as a conduit to fund co-payments of thousands of Medicare patients t

News

Teva charged in US price-fixing investigation

The US Department of Justice has charged Teva with conspiring with other pharma companies to fix prices for generic drugs.

EU panel rejects Pfizer's tanezumab for osteoarthritis pain

Teva faces EU antitrust probe over MS drug Copaxone

EU fines Teva and Cephalon €60.5m for 'pay for delay' scheme

NICE backs Lilly’s Emgality for migraine, adding pressure on...

Gilead pays $97m to resolve US illegal kickback claims

Teva charged in US price-fixing investigation

CHMP backs Novo's haemophilia A drug Frehemgo

Discover a new era of healthcare panel engagement: Grounded ...

Teva

Editor's Picks